HOME >> BIOLOGY >> NEWS
Failure of critical protein connection at heart of cardiomyopathy

HOUSTON--(March 16, 2002)--The failure of dystrophin, one of the building blocks that literally holds heart muscle cells together, can cause dilated cardiomyopathy (DCM), a condition in which the pumping chambers of the heart enlarge and cannot pump adequately, according to researchers at Baylor College of Medicine in a report in todays issue of the journal The Lancet.

However, allowing the heart to rest by using a mechanical device called a ventricular assist device or VAD allows dystrophin to resume its function and restores the heart to more normal pumping, said Dr. Jeffrey Towbin, professor of pediatrics and cardiology at Baylor and the senior author of the report.

Dystrophin is probably best known for its relationship to Duchenne and Becker muscular dystrophy, diseases in which the muscles weaken, the child requires a wheelchair and dilated cardiomyopathy occurs. A mutation in the dystrophin gene causes these diseases.

However, in the case of dilated cardiomyopathy alone, the end portion of the dystrophin protein loses a critical connection between the cells contractile apparatus and the cellular membrane. As a result, the heart cannot contract adequately, said Drs. Jeffrey Towbin and Neil Bowles, also a member of the Baylor research team.

Towbin and his colleagues took samples from 10 patients with ischemic (disease of the coronary artery) and 10 patients with non-ischemic dilated cardiomyopathies resulting from different causes who were awaiting heart transplants. Samples were also obtained from six patients with dilated cardiomyopathy who were being treated with these ventricular assist pumps. They compared the patient samples to normal samples taken from transplanted hearts and found the abnormality in the dystrophin of roughly 90 percent of all the patients with cardiomyopathy.

There are two theories about why the protein becomes disconnected. One is mechanical. As the heart pumps harder and harder over a number o
'"/>

Contact: Lori Williams/Ron Gilmore
rgilmore@bcm.tmc.edu
713-798-4712
Baylor College of Medicine
14-Mar-2002


Page: 1 2

Related biology news :

1. Failure of DNA repair mechanism precedes final stage of deadly leukemia, new Penn study shows
2. Failures in primate cloning may signal impossibility of human reproductive cloning
3. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
4. Duke Scientist Reports Advances In Gene Therapy For Heart Failure
5. Local Approaches To Combating Antibiotic Resistance Are Doomed To Failure
6. Circulatory Device -- A Bridge To Recovery For Heart Failure?
7. Molecular Key To Heart Failure Development
8. Gene-Altered Mice Boost Studies of Cardiomyopathy: Enables Research Into Causes And Treatment Of Heart Failure
9. Possible Trigger For Heart Failure Identified In Lab Animal Studies
10. UCSD team determines cellular stress within body is critical
11. Carnegie Mellon U biologists identify critical player in yeast ribosome assembly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... ... NDA Partners Chairman Carl Peck, MD, announced today that Deb Koeneman, ... and Radiological Health (CDRH), has been appointed a Partner in the firm. Ms. Koeneman ... more than 25 years of regulatory experience. In addition to her FDA career, she ...
(Date:12/18/2018)... ... December 18, 2018 , ... The nation’s ... into client marketing. The technology has been effective at reducing patient acquisition costs ... been working with clients nationwide on patient acquisition marketing programs. Traditional marketing for ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today announced ... candidate, code-named "KM-819." KM-819 is an orally active small molecule that is ... Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to ...
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection and ... in regulations in the European Union (EU) on the horizon, Jim Kasic, president and ... “The transition to the EU Medical Device Regulation (MDR), digital health, and big data ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group ... This has been part of their strategic plan and an important milestone in ... custom fermentation opportunities for MDG within the $44 Billion human probiotic market. This ...
Breaking Biology Technology:
Cached News: